PTLD
MCID: PST046
MIFTS: 54

Post-Transplant Lymphoproliferative Disease (PTLD) malady

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Post-Transplant Lymphoproliferative Disease

Aliases & Descriptions for Post-Transplant Lymphoproliferative Disease:

Name: Post-Transplant Lymphoproliferative Disease 38 50 56
Post-Transplant Lymphoproliferative Disorder 69
Ptld 56

Characteristics:

Orphanet epidemiological data:

56
post-transplant lymphoproliferative disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

Orphanet 56 ORPHA70568
UMLS via Orphanet 70 C0432487
ICD10 via Orphanet 34 D47.9

Summaries for Post-Transplant Lymphoproliferative Disease

MalaCards based summary : Post-Transplant Lymphoproliferative Disease, also known as post-transplant lymphoproliferative disorder, is related to hepatitis and lyme disease. An important gene associated with Post-Transplant Lymphoproliferative Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Benzocaine and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include b cells, liver and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Wikipedia : 71 Post-transplant lymphoproliferative disorder (PTLD) is the name given to a B-cell proliferation due to... more...

Related Diseases for Post-Transplant Lymphoproliferative Disease

Diseases related to Post-Transplant Lymphoproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.3 IL10 IL6 TNF
2 lyme disease 11.1
3 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
4 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 TNF
5 lagophthalmos 10.3 IL10 TNF
6 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 IL6 TNF
7 autosomal recessive pericentral pigmentary retinopathy 10.3 TNF TNFRSF1A
8 occupational dermatitis 10.3 TNF TNFRSF1B
9 cryptococcosis 10.2 IL10 TNF TNFRSF1B
10 multiple epiphyseal dysplasia 10.2 TNF TNFRSF1A TNFRSF1B
11 conjunctival vascular disease 10.2 TNF TNFRSF1A TNFRSF1B
12 candidiasis, familial, 4, autosomal recessive 10.2 TNF TNFRSF1A
13 lymphoma 10.2
14 acinic cell breast carcinoma 10.2 TNF TNFRSF1A TNFRSF1B
15 idiopathic hypertrophic pachymeningitis 10.2 IL10 LTA TNF
16 spondylometaphyseal dysplasia east-african type 10.2 B2M LTA TNF
17 vestibule of mouth cancer 10.2 IL10 LTA TNF
18 choreatic disease 10.2 TNF TNFRSF1A TNFRSF1B
19 celiac disease 10.2 TNF TNFRSF1A TNFRSF1B
20 cyclosporiasis 10.2 IL10 IL6 TNF
21 hypoparathyroidism-retardation-dysmorphism syndrome 10.2 IL10 IL6 TNF
22 trichomalacia 10.2 IL10 IL6 TNF
23 dengue hemorrhagic fever 10.2 IL10 SLC11A1 TNF
24 phlyctenulosis 10.2 IL10 IL6 TNF
25 conduct disorder 10.2 IL10 IL6 TNF
26 benign eccrine breast spiradenoma 10.2 IL10 SLC11A1 TNF
27 gastric dilatation 10.2 IL10 IL6 TNF
28 pancreatic signet ring cell adenocarcinoma 10.2 IL10 IL6 TNF
29 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.2 IL10 IL6 TNF
30 gonococcal endophthalmia 10.2 IL10 IL6 TNF
31 ectodermal dysplasia bartalos type 10.2 IL10 IL6 TNF
32 liver inflammatory pseudotumor 10.2 IL10 SLC11A1 TNF
33 bladder signet ring cell adenocarcinoma 10.2 IL10 IL6 TNF
34 erb-duchenne and dejerine-klumpke palsies 10.2 IL10 IL6 TNF
35 orbital osteomyelitis 10.2 IL10 IL6 TNF
36 central nervous system lymphoma 10.2 IL10 IL6 TNF
37 tuberculosis 10.2 IL10 IL6 TNF
38 labyrinthitis 10.2 IL10 IL6 TNF
39 holocarboxylase synthetase deficiency 10.2 IL10 IL10RA
40 dyslexia 5 10.2 IL6 TNF
41 disease of mental health 10.2 IL10 IL6 TNF
42 atrophy of prostate 10.2 IL10 IL6 TNF
43 senile reticular retinal degeneration 10.2 IL10 IL1R1 TNF
44 follicular adenoma 10.2 IL10 IL6 TNF
45 human immunodeficiency virus infectious disease 10.2 IL6 TNF TNFRSF10A
46 alcoholic hepatitis 10.2 IL10 IL6 TNF
47 chordoid meningioma 10.2 IL10 IL6 TNF
48 choroiditis 10.2 IL10 IL6 TNF
49 depressed scar 10.2 IL10 IL6 TNF
50 mansonelliasis 10.2 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Post-Transplant Lymphoproliferative Disease:



Diseases related to Post-Transplant Lymphoproliferative Disease

Symptoms & Phenotypes for Post-Transplant Lymphoproliferative Disease

GenomeRNAi Phenotypes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 IL10 IL1A LTA CASP8 TNF FADD
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 IL10 IL1A LTA CASP8 TNF FADD

MGI Mouse Phenotypes related to Post-Transplant Lymphoproliferative Disease:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 TNFRSF1A TNFRSF1B TNFSF10 B2M CASP8 FADD
2 cardiovascular system MP:0005385 10.35 B2M CASP8 FADD IL10 IL1A IL1R1
3 immune system MP:0005387 10.35 B2M CASP8 FADD IL10 IL10RA IL1A
4 homeostasis/metabolism MP:0005376 10.34 FADD IL10 IL10RA IL1A IL1R1 IL6
5 endocrine/exocrine gland MP:0005379 10.31 IL10 IL1R1 IL6 LTA TNF TNFRSF10A
6 cellular MP:0005384 10.3 IL6 TNF TNFRSF10A TNFRSF1A TNFRSF1B B2M
7 growth/size/body region MP:0005378 10.22 B2M CASP8 FADD IL10 IL1R1 IL6
8 mortality/aging MP:0010768 10.22 SLC11A1 TNF TNFRSF10A TNFRSF1A TNFRSF1B B2M
9 digestive/alimentary MP:0005381 10.2 B2M FADD IL10 IL10RA IL6 SLC11A1
10 liver/biliary system MP:0005370 10.17 TNFSF10 B2M CASP8 FADD IL10 IL1R1
11 integument MP:0010771 10.11 B2M CASP8 IL10 IL1A IL1R1 IL6
12 neoplasm MP:0002006 10.1 B2M CASP8 IL10 IL1A IL1R1 IL6
13 muscle MP:0005369 9.97 CASP8 FADD IL10 IL1R1 IL6 TNF
14 nervous system MP:0003631 9.96 LTA TNF TNFRSF1A TNFRSF1B B2M CASP8
15 respiratory system MP:0005388 9.76 CASP8 IL10 IL1R1 IL6 LTA TNF
16 skeleton MP:0005390 9.61 FADD IL10 IL1R1 IL6 LTA TNF
17 vision/eye MP:0005391 9.17 IL10 IL1R1 IL6 LTA TNF TNFRSF1A

Drugs & Therapeutics for Post-Transplant Lymphoproliferative Disease

Drugs for Post-Transplant Lymphoproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
2
Everolimus Approved Phase 4,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
5
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
6
Pancrelipase Approved Phase 4 53608-75-6
7
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
10
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2 23214-92-8 31703
11
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
12
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
13
Vidarabine Approved Phase 4,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
14
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
15 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 1
16
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2 31703
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 pancreatin Phase 4
26 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
34
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
35
Busulfan Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 55-98-1 2478
36
Cyclosporine Approved, Investigational, Vet_approved Phase 2, Phase 3, Phase 1, Early Phase 1 79217-60-0, 59865-13-3 5284373 6435893
37
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 83-43-2 6741
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1 50-24-8 5755
39
Lenograstim Approved Phase 2, Phase 3, Phase 1, Early Phase 1 135968-09-1
40
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
41
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
42
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
43
Melphalan Approved Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
44
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
45
Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
46
Mechlorethamine Approved Phase 2, Phase 3,Phase 1,Early Phase 1 51-75-2 4033
47
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
48
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
49
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
50
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 346)
id Name Status NCT ID Phase
1 A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4
2 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4
3 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4
4 Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation Unknown status NCT00033475 Phase 3
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
6 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3
7 Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3
8 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
13 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
14 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Completed NCT00083551 Phase 3
15 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3
16 Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00070187 Phase 2, Phase 3
17 Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients Completed NCT00213590 Phase 3
18 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
19 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3
20 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
21 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3
22 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Recruiting NCT02451033 Phase 2, Phase 3
23 Autologous Transplant for Multiple Myeloma Recruiting NCT00177047 Phase 2, Phase 3
24 Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT Recruiting NCT03066466 Phase 3
25 Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma Recruiting NCT02406144 Phase 3
26 Maintenance Therapy Using Lenalidomide in Myeloma Active, not recruiting NCT00430365 Phase 3
27 Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer Not yet recruiting NCT02999854 Phase 3
28 Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Terminated NCT00714259 Phase 2, Phase 3
29 Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma Terminated NCT00083564 Phase 3
30 Stem Cell Transplantation for Hematological Malignancies Terminated NCT00176839 Phase 2, Phase 3
31 Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Unknown status NCT02007811 Phase 1, Phase 2
32 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2
33 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Unknown status NCT00691015 Phase 2
34 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
35 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
36 Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas Unknown status NCT02049580 Phase 2
37 Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) Unknown status NCT00632827 Phase 2
38 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
39 Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Unknown status NCT00304720 Phase 2
40 Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON) Unknown status NCT01325896 Phase 2
41 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
42 Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation Unknown status NCT01491958 Phase 2
43 Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma Unknown status NCT00907036 Phase 2
44 Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Unknown status NCT00908180 Phase 2
45 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Completed NCT00064246 Phase 1, Phase 2
46 Risk Stratified Sequential Treatment for CD20-positive PTLD Completed NCT00590447 Phase 2
47 Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Completed NCT00307125 Phase 2
48 Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation Completed NCT01208337 Phase 2
49 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
50 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2

Search NIH Clinical Center for Post-Transplant Lymphoproliferative Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Post-Transplant Lymphoproliferative Disease:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Post-Transplant Lymphoproliferative Disease:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Post-Transplant Lymphoproliferative Disease

Anatomical Context for Post-Transplant Lymphoproliferative Disease

MalaCards organs/tissues related to Post-Transplant Lymphoproliferative Disease:

39
B Cells, Liver, Lung, Heart, Bone, T Cells, Kidney

Publications for Post-Transplant Lymphoproliferative Disease

Articles related to Post-Transplant Lymphoproliferative Disease:

(show top 50) (show all 149)
id Title Authors Year
1
Comment on: Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26944670 )
2016
2
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. ( 27467959 )
2016
3
Persistent Epstein-Barr viral load in Epstein-Barr viral naA^ve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease. ( 28058224 )
2016
4
The Role of Antiviral Prophylaxis for the Prevention of Epstein Barr Virus Associated Post-transplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. ( 27545492 )
2016
5
Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lymphoproliferative disease of Hodgkin's type: a diagnostic challenge. ( 26239296 )
2015
6
FDG-PET/CT in Abdominal Post-Transplant Lymphoproliferative Disease. ( 26544161 )
2015
7
Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study. ( 26155195 )
2015
8
Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. ( 25936966 )
2015
9
How Should We Treat Early Post-Transplant Lymphoproliferative Disease After Heart Transplantation? ( 26549285 )
2015
10
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. ( 25686696 )
2015
11
Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26279197 )
2015
12
Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. ( 25843801 )
2015
13
Post-transplant lymphoproliferative disease and other malignancies after pediatric cardiac transplantation: an evolving landscape. ( 26262461 )
2015
14
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. ( 25845981 )
2015
15
Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report. ( 26361705 )
2015
16
Array CGH-based analysis of post-transplant plasmacytic hyperplasia reveals 'intact genomes' arguing against categorizing it as part of the post-transplant lymphoproliferative disease spectrum. ( 25041332 )
2014
17
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. ( 24399278 )
2014
18
CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target. ( 25242095 )
2014
19
Breast involvement with post-transplant lymphoproliferative disease in a renal transplant recipient. ( 24034058 )
2013
20
Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease. ( 24335998 )
2013
21
Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. ( 23802715 )
2013
22
Isolated post-transplantation lymphoproliferative disease involving the breast and axilla as peripheral T-cell lymphoma. ( 24043963 )
2013
23
Epistaxis in a kidney transplant recipient: an uncommon presentation of post-transplant lymphoproliferative disease. ( 23577919 )
2013
24
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. ( 23737188 )
2013
25
Risk factors for Epstein Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. ( 24056821 )
2013
26
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. ( 21584931 )
2012
27
Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease. ( 22554096 )
2012
28
Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus. ( 23498038 )
2012
29
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. ( 22711849 )
2012
30
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. ( 22801669 )
2012
31
Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm. ( 22915052 )
2012
32
Adult post-transplant lymphoproliferative disease in the liver graft in patients with recurrent hepatitis C. ( 21555941 )
2011
33
CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. ( 21275950 )
2011
34
Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. ( 21518001 )
2011
35
CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. ( 21559814 )
2011
36
Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. ( 21056103 )
2011
37
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). ( 21294246 )
2011
38
Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. ( 20345506 )
2010
39
Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). ( 20493424 )
2010
40
The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. ( 20070559 )
2010
41
Tonsillectomy in post-transplant lymphoproliferative disease in children. ( 20131364 )
2010
42
Post-transplant lymphoproliferative disease. ( 17891420 )
2009
43
Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring. ( 19017289 )
2009
44
Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation. ( 19664018 )
2009
45
Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. ( 19738620 )
2009
46
Associations of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease. ( 19200218 )
2009
47
Post-transplant lymphoproliferative disease presenting as a mass in the left ventricle in a heart transplant recipient at long-term follow-up. ( 19201350 )
2009
48
Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. ( 19497070 )
2009
49
Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. ( 18466428 )
2008
50
Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. ( 18564989 )
2008

Variations for Post-Transplant Lymphoproliferative Disease

Expression for Post-Transplant Lymphoproliferative Disease

Search GEO for disease gene expression data for Post-Transplant Lymphoproliferative Disease.

Pathways for Post-Transplant Lymphoproliferative Disease

Pathways related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 B2M CASP8 FADD IL10 IL10RA IL1A
2
Show member pathways
13.87 CASP8 FADD IL6 LTA TNF TNFRSF10A
3
Show member pathways
13.85 CASP8 FADD IL10 IL10RA IL1A IL1R1
4
Show member pathways
13.65 CASP8 IL10 IL10RA IL1A IL1R1 IL6
5
Show member pathways
13.56 IL10 IL10RA IL1A IL1R1 IL6 LTA
6
Show member pathways
13.4 B2M IL10 IL10RA IL1A IL1R1 IL6
7
Show member pathways
13.33 FADD IL10 IL10RA IL1A IL1R1 IL6
8
Show member pathways
13.1 CASP8 IL10 IL10RA IL1A IL1R1 IL6
9
Show member pathways
13.03 CASP8 FADD IL1A IL1R1 IL6 TNF
10
Show member pathways
12.96 CASP8 FADD IL10 IL6 TNF TNFRSF1A
11
Show member pathways
12.95 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
12
Show member pathways
12.94 CASP8 FADD IL6 TNF TNFRSF10A TNFRSF1A
13
Show member pathways
12.92 B2M CASP8 FADD IL10 IL1A IL6
14
Show member pathways
12.83 CASP8 FADD IL1R1 TNFRSF10A TNFSF10
15
Show member pathways
12.82 IL6 LTA TNF TNFRSF1A TNFRSF1B
16
Show member pathways
12.82 CASP8 FADD IL1R1 LTA TNF TNFRSF10A
17
Show member pathways
12.78 CASP8 FADD IL1A IL6 LTA TNF
18
Show member pathways
12.77 FADD IL1A IL1R1 IL6 LTA TNF
19 12.76 CASP8 IL1A IL1R1 TNF TNFRSF1A
20
Show member pathways
12.74 IL1A IL1R1 LTA TNF TNFRSF1A TNFRSF1B
21
Show member pathways
12.68 IL10 IL10RA TNF TNFRSF1A TNFRSF1B
22
Show member pathways
12.65 IL10 IL1A IL1R1 IL6 TNF
23 12.6 B2M IL10 TNF TNFRSF1A TNFRSF1B
24
Show member pathways
12.59 IL10 IL10RA IL6 TNF
25
Show member pathways
12.58 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
26 12.5 IL1R1 IL6 LTA TNF TNFRSF1A
27
Show member pathways
12.46 IL10 IL1A IL6 TNF
28
Show member pathways
12.39 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
29
Show member pathways
12.37 CASP8 FADD IL6 TNF
30
Show member pathways
12.36 CASP8 IL10 IL10RA IL1A TNF TNFRSF1A
31
Show member pathways
12.34 CASP8 FADD TNFRSF10A TNFSF10
32
Show member pathways
12.34 CASP8 FADD IL1A TNF TNFRSF1A
33 12.34 CASP8 FADD TNFRSF10A TNFRSF1A TNFRSF1B TNFSF10
34
Show member pathways
12.32 IL1A IL1R1 IL6 TNF
35
Show member pathways
12.25 IL10 IL1A IL6 LTA TNF
36 12.23 IL10 IL1A IL6 TNF
37
Show member pathways
12.18 CASP8 FADD TNF TNFRSF1A
38
Show member pathways
12.18 CASP8 FADD IL1A IL1R1 LTA TNF
39 12.16 IL1A IL1R1 TNF TNFRSF1A
40 12.12 IL1A IL1R1 TNF TNFRSF1A
41
Show member pathways
12.09 CASP8 FADD TNF TNFRSF1A
42 12.08 IL1A IL1R1 IL6 TNF
43 12.08 IL10 IL1A IL6 TNF TNFRSF1B
44
Show member pathways
12.03 CASP8 IL1A IL1R1
45
Show member pathways
12.02 IL10 IL6 LTA TNF
46 12.01 CASP8 FADD IL10 IL10RA IL1A IL6
47 12 IL10 IL6 TNF
48
Show member pathways
11.99 TNF TNFRSF1A TNFRSF1B
49 11.98 IL1A IL1R1 IL6 TNF
50
Show member pathways
11.97 IL6 TNF TNFRSF1A

GO Terms for Post-Transplant Lymphoproliferative Disease

Cellular components related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 IL1R1 SLC11A1 TNF TNFRSF10A TNFRSF1A TNFRSF1B
2 cell surface GO:0009986 9.83 B2M IL1R1 TNF TNFRSF10A TNFRSF1A
3 extracellular space GO:0005615 9.76 B2M IL10 IL1A IL6 LTA TNF
4 death-inducing signaling complex GO:0031264 9.37 CASP8 FADD
5 membrane raft GO:0045121 9.35 CASP8 FADD TNF TNFRSF1A TNFRSF1B
6 ripoptosome GO:0097342 9.32 CASP8 FADD
7 extracellular region GO:0005576 9.32 B2M IL10 IL1A IL1R1 IL6 LTA
8 CD95 death-inducing signaling complex GO:0031265 9.26 CASP8 FADD

Biological processes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
id Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.99 IL10 SLC11A1 TNF TNFRSF1A
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.98 CASP8 FADD TNF TNFRSF1A TNFSF10
3 cytokine-mediated signaling pathway GO:0019221 9.97 IL10RA IL1A IL1R1 IL6 TNFRSF1A
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.96 LTA TNF TNFRSF10A TNFRSF1A TNFRSF1B
5 cellular response to lipopolysaccharide GO:0071222 9.95 B2M IL10 IL6 TNF TNFRSF1B
6 cell surface receptor signaling pathway GO:0007166 9.95 CASP8 FADD IL1R1 TNFRSF10A TNFRSF1A TNFRSF1B
7 cellular response to mechanical stimulus GO:0071260 9.91 CASP8 FADD TNFRSF10A TNFRSF1A
8 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.9 IL10 IL6 TNF
9 apoptotic signaling pathway GO:0097190 9.9 CASP8 FADD TNF TNFRSF1B
10 defense response to Gram-positive bacterium GO:0050830 9.89 B2M IL6 LTA TNF
11 negative regulation of inflammatory response GO:0050728 9.88 IL10 TNFRSF1A TNFRSF1B
12 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.88 CASP8 FADD TNF TNFRSF10A TNFSF10
13 response to glucocorticoid GO:0051384 9.87 IL10 IL6 TNF
14 response to insulin GO:0032868 9.87 IL10 IL6 TNFSF10
15 positive regulation of interferon-gamma production GO:0032729 9.87 FADD LTA SLC11A1 TNF
16 inflammatory response GO:0006954 9.86 IL10 IL1A IL6 SLC11A1 TNF TNFRSF10A
17 humoral immune response GO:0006959 9.85 IL6 LTA TNF
18 defense response to Gram-negative bacterium GO:0050829 9.85 B2M IL6 SLC11A1
19 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.84 TNF TNFRSF1A TNFRSF1B
20 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.84 CASP8 FADD TNFRSF10A TNFSF10
21 positive regulation of interleukin-6 production GO:0032755 9.83 IL1A IL6 TNF
22 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.81 CASP8 TNF TNFRSF1A
23 positive regulation of cytokine secretion GO:0050715 9.81 IL10 IL1A TNF
24 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.81 FADD TNF TNFRSF10A TNFRSF1A
25 defense response to protozoan GO:0042832 9.8 IL10 IL6 SLC11A1
26 negative regulation of growth of symbiont in host GO:0044130 9.78 IL10 LTA TNF
27 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.73 IL10 TNF
28 positive regulation of chemokine production GO:0032722 9.73 IL6 TNF
29 iron ion transport GO:0006826 9.73 B2M SLC11A1
30 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.73 TNF TNFRSF1B
31 lymph node development GO:0048535 9.73 FADD LTA
32 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.73 CASP8 FADD TNFRSF10A TNFSF10
33 cellular response to hepatocyte growth factor stimulus GO:0035729 9.72 IL10 IL6
34 interleukin-1-mediated signaling pathway GO:0070498 9.72 IL1A IL1R1
35 positive regulation of macrophage differentiation GO:0045651 9.72 CASP8 FADD
36 response to molecule of bacterial origin GO:0002237 9.72 B2M IL10
37 extrinsic apoptotic signaling pathway GO:0097191 9.72 CASP8 FADD TNF TNFRSF10A TNFRSF1B
38 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
39 positive regulation of T cell mediated cytotoxicity GO:0001916 9.71 B2M FADD
40 regulation of necroptotic process GO:0060544 9.71 CASP8 FADD
41 activation of cysteine-type endopeptidase activity GO:0097202 9.71 CASP8 FADD
42 negative regulation of lipid storage GO:0010888 9.7 IL6 TNF
43 regulation of synapse organization GO:0050807 9.7 IL10 IL10RA
44 positive regulation of ceramide biosynthetic process GO:2000304 9.7 TNF TNFRSF1A
45 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
46 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF TNFRSF1A
47 necroptotic signaling pathway GO:0097527 9.68 FADD TNF
48 negative regulation of cytokine secretion involved in immune response GO:0002740 9.68 IL10 TNF
49 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.68 IL6 TNF
50 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.67 CASP8 FADD TNFRSF10A TNFSF10

Molecular functions related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.46 FADD IL1R1 TNF TNFRSF10A
2 tumor necrosis factor-activated receptor activity GO:0005031 9.43 TNFRSF10A TNFRSF1A TNFRSF1B
3 cytokine activity GO:0005125 9.43 IL10 IL1A IL6 LTA TNF TNFSF10
4 death receptor binding GO:0005123 9.4 CASP8 FADD
5 tumor necrosis factor receptor superfamily binding GO:0032813 9.37 FADD TNFSF10
6 death effector domain binding GO:0035877 9.32 CASP8 FADD
7 tumor necrosis factor receptor binding GO:0005164 9.02 CASP8 FADD LTA TNF TNFSF10

Sources for Post-Transplant Lymphoproliferative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....